Omburtamab I-124 - Y-mAbs Therapeutics

Drug Profile

Omburtamab I-124 - Y-mAbs Therapeutics

Alternative Names: 124I-8H9; 124I-8H9 (B7-H3)

Latest Information Update: 09 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Weill Cornell Medical College
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioma

Most Recent Events

  • 02 Jun 2017 Safety and Pharmacokinetics data from a phase I trial in Glioma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 18 Nov 2016 The US FDA grants Y-mAbs Therapeutics a rare pediatric disease designation for 8H9I-124 for the treatment of diffuse intrinsic pontine glioma
  • 09 Sep 2016 Phase-I/II clinical trials in Glioma in USA (Infusion) (Y-mAbs Therapeutics pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top